Group 1 - The core issue raised by investors is the lack of announcement regarding the completion of the Phase III clinical trial for the VGX-3100 vaccine developed by Beijing Oriental Lue [1] - The company, Dezhan Health, stated that the Phase III clinical trial for VGX-3100, which targets HPV-16 and/or HPV-18 related high-grade cervical precancerous lesions, has completed patient enrollment [1] - As of now, the Phase III clinical trial has not been fully completed, and the company will fulfill its information disclosure obligations as required by regulations if there are any relevant matters concerning Oriental Lue [1]

Core Viewpoint - The company has not yet engaged in the commercial application of AI but is closely monitoring its development and trends in the pharmaceutical and healthcare industry [2]. Group 1 - An investor inquired about the company's plans regarding AI in the pharmaceutical sector [2]. - The company stated that it will focus on its main business while keeping an eye on the application and development trends of AI and other cutting-edge technologies in the healthcare industry [2].

Group 1 - The company, Dezhan Health (000813.SZ), has stated that it is currently not involved in the commercial application of AI [1] - The company will focus on its main business while closely monitoring the application and development trends of AI and other cutting-edge technologies in the pharmaceutical and health industry [1]

（文章来源：证券日报） 证券日报网讯 9月16日晚间，德展健康发布公告称，公司聘任吴金童先生为公司证券事务代表。 ...

Group 1 - The company, Dezhan Health (000813.SZ), announced the election of Wei Zheming as the chairman of the ninth board of directors and Liu Wei as the co-chairman for a term of three years, aligning with the board's term [1]

证券代码：000813 证券简称：德展健康 公告编号：2025-070 德展大健康股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司""德展健康"）于 2025 年 9 月 16 日召开第九届董事会第一次会议，选举产生公司董事长、联席董事长、各专 门委员会委员，并聘任第九届高级管理人员、证券事务代表。现将有关事项公告 如下： 一、公司选举第九届董事会董事长、联席董事长情况 关于选举董事长、联席董事长及聘任高级管理人员、 证券事务代表等事项的公告 根据《公司法》《上市公司治理准则》《公司章程》等的有关规定，为规范公 司治理，保证董事会有序、高效、规范运作，经公司第九届董事会第一次会议审 议通过，选举魏哲明先生为第九届董事会董事长；选举刘伟先生为第九届董事会 联席董事长，任期三年，与公司第九届董事会任期一致。上述人员简历详见附件。 二、公司第九届董事会专门委员会组成情况 为进一步完善公司治理结构，健全董事会决策机制，充分发挥董事会专门委 员会的专业职能和议事效能，为董事会科学决策提供有力支持，根据《公司法》 《公司 ...

第九届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 德展大健康股份有限公司（以下简称"公司""德展健康"）第九届董事会第 一次会议的通知已于 2025 年 9 月 13 日以电子邮件方式发出；公司于 2025 年 9 月 16 日 11:00 以现场结合通讯表决方式在公司新疆办公区会议室召开。本次会 议应参加会议董事 9 人，实际参加会议董事 9 人。会议由全体董事共同推举董事 魏哲明先生主持，高管候选人列席了本次会议。本次会议的召集、召开符合《公 司法》及《公司章程》的规定。 二、董事会会议审议情况 （一）关于选举魏哲明先生为公司董事长的议案 证券代码：000813 证券简称：德展健康 公告编号：2025-069 德展大健康股份有限公司 表决结果：同意 9 票，反对 0 票，弃权 0 票。 该议案审议获得通过。 （二）关于选举刘伟先生为公司联席董事长的议案 表决结果：同意 9 票，反对 0 票，弃权 0 票。 该议案审议获得通过。 （三）关于选举第九届董事会各专门委员会委员的议案 表决结果：同意 9 票，反 ...

Group 1 - The CRO concept sector rose by 1.44%, ranking 8th among concept sectors, with 42 stocks increasing in value, including notable gainers such as Dezheng Health, Zhaoyan New Drug, and ST Weiming, which hit the daily limit, while Boteng Co., Haofan Bio, and Kanglong Chemical saw significant increases of 9.21%, 9.10%, and 6.37% respectively [1][2] - The sector experienced a net inflow of 778 million yuan from main funds, with 35 stocks receiving net inflows, and 7 stocks attracting over 50 million yuan, led by Kanglong Chemical with a net inflow of 172 million yuan, followed by Kailaiying, WuXi AppTec, and Dezheng Health with net inflows of 159 million yuan, 148 million yuan, and 148 million yuan respectively [2][3] Group 2 - In terms of fund inflow ratios, Dezheng Health, Haoyuan Pharmaceutical, and New World had the highest net inflow ratios at 30.08%, 12.93%, and 11.07% respectively [3] - The CRO concept fund inflow rankings showed that Kanglong Chemical had a daily increase of 6.37% with a turnover rate of 6.31%, while Kailaiying and WuXi AppTec also performed well with increases of 4.11% and 1.45% respectively [4][5] - The overall performance of the CRO sector was mixed, with some stocks like ST Weiming and *ST Shuangcheng experiencing declines of 2.19% and 1.92% respectively, indicating volatility within the sector [1][6]

Group 1 - The innovative drug concept stocks experienced a significant surge, with Dezheng Health hitting the daily limit up [1] - Other companies such as Boteng Co., Zhaoyan New Drug, Enhua Pharmaceutical, Kangchen Pharmaceutical, and Shanghai Yizhong also saw increases in their stock prices [1]

德展大健康股份有限公司章程 （2025 年 9 月修订） 第一章 总 则 1.1.2 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下简称"公司"）。 公司经中华人民共和国对外贸易经济合作部【1994】外经贸资函字第 576 号文《关于 设立新疆天山毛纺织股份有限公司的批复》批准，由新疆乌鲁木齐天山毛纺织公司、香港 天山毛纺织有限公司、香港国际棉业有限公司、新疆维吾尔自治区供销合作社联合社四家 单位为发起人，以发起方式设立；在乌鲁木齐市市场监督管理局注册登记，取得营业执照 〔统一社会信用代码：916500006255547591〕。 | 第一章 | 总 则 | | 2 | | --- | --- | --- | --- | | 第二章 | 经营宗旨及范围 | | 3 | | 第三章 | 股 份 | | 3 | | 第四章 | 股东和股东会 | | 6 | | 第五章 | 董事和董事会 | | 20 | | 第六章 | 高级管理人员 | | 31 | | 第七章 | 党组织 | | 32 | | 第八章 | 财务会计制度、利润分配和审计 | | 33 | | 第九章 | 通知和公告 | | 37 | ...